Scholarlink

<p>Irisin is a peptide hormone with notable anti-inflammatory and metabolic regulatory effects but has limited clinical utility due to its extremely short plasma half-life (&lt; 1 h). In this study, we engineered an albumin-binding domain (ABD)-conjugated Irisin (ABD-Irisin) fusion protein to significantly extend half-life and enhance therapeutic potency. ABD-Irisin fusion protein was successfully expressed in HEK-293F cells, purified, and validated through functional assays including lipid droplet reduction and western blot assays. Pharmacokinetic studies demonstrated that ABD-Irisin markedly prolonged the plasma half-life of Irisin to approximately 10 h, substantially surpassing native Irisin, and showed enhanced tissue distribution in vivo. In a lipopolysaccharide (LPS) induced mouse model of systemic inflammation, both Irisin and ABD-Irisin significantly reduced plasma TNF-α levels, splenomegaly, and histopathological inflammation. Notably, ABD-Irisin (500 μg/kg) demonstrated significantly enhanced suppression of plasma IL-6 and splenic inflammatory cytokines (IL-1β, IL-10) compared to native Irisin. Single-cell RNA sequencing further revealed that ABD-Irisin robustly suppressed the activation of the TLR4-MyD88-NF-κB signaling axis in bone marrow immune cells, outperforming unmodified Irisin. These findings demonstrate that ABD conjugation is an effective strategy to enhance the pharmacokinetics and anti-inflammatory efficacy of Irisin, highlighting ABD-Irisin as a promising therapeutic candidate for inflammatory diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered long-acting Irisin-albumin binding domain fusion protein for enhanced anti-inflammatory efficacy in lipopolysaccharide-induced systemic inflammation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Jicun Zhu,
  • Yujie Zhang,
  • Xinwei Wang,
  • Lei Peng,
  • Xiaojia Ma,
  • Zan Qiu,
  • Zirui Kang,
  • Fangyuan Zheng,
  • Xiaoyu Zhang,
  • Mengyuan Song,
  • Jia Du,
  • Yuan Shi,
  • Lie Yu,
  • Chenxi Gu,
  • Jianxiang Shi

摘要

Irisin is a peptide hormone with notable anti-inflammatory and metabolic regulatory effects but has limited clinical utility due to its extremely short plasma half-life (< 1 h). In this study, we engineered an albumin-binding domain (ABD)-conjugated Irisin (ABD-Irisin) fusion protein to significantly extend half-life and enhance therapeutic potency. ABD-Irisin fusion protein was successfully expressed in HEK-293F cells, purified, and validated through functional assays including lipid droplet reduction and western blot assays. Pharmacokinetic studies demonstrated that ABD-Irisin markedly prolonged the plasma half-life of Irisin to approximately 10 h, substantially surpassing native Irisin, and showed enhanced tissue distribution in vivo. In a lipopolysaccharide (LPS) induced mouse model of systemic inflammation, both Irisin and ABD-Irisin significantly reduced plasma TNF-α levels, splenomegaly, and histopathological inflammation. Notably, ABD-Irisin (500 μg/kg) demonstrated significantly enhanced suppression of plasma IL-6 and splenic inflammatory cytokines (IL-1β, IL-10) compared to native Irisin. Single-cell RNA sequencing further revealed that ABD-Irisin robustly suppressed the activation of the TLR4-MyD88-NF-κB signaling axis in bone marrow immune cells, outperforming unmodified Irisin. These findings demonstrate that ABD conjugation is an effective strategy to enhance the pharmacokinetics and anti-inflammatory efficacy of Irisin, highlighting ABD-Irisin as a promising therapeutic candidate for inflammatory diseases.